Medications

FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA

(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...

Diseases, Conditions, Syndromes

Targeted antisense oligonucleotide drug tested in humans

A first-in-human study with a new class of antisense oligonucleotide therapeutics showed the ability to target the RNA-silencing drug to the liver, resulting in improved potency and safety at therapeutic doses. The design ...

Medical research

UK must not fall behind in race to 'humanize' drug discovery

Researchers writing in the Journal of the Royal Society of Medicine are warning that current research models and regulation are blocking the development of human-relevant approaches to drug discovery and are perpetuating ...

Cardiology

Study explores timing of muscle-related problems of statin use

Statins have been linked with muscle pain and other musculoskeletal adverse events (MAEs) in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy ...

page 12 from 29